SCHEMBL792527

SCHEMBL792527

CC(=O)c1ccc2c(C)c3n(c2c1)CCCC3

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.41
GAA P10253 2/20 0.41
ALOX15 P16050 1/20 0.41
TP53 P04637 2/20 0.41
POLB P06746 3/20 0.41
THRB P10828 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.38
SIGMAR1 Q99720 1/20 0.38
MAPK1 P28482 1/20 0.38
CNR1 P21554 1/20 0.37
CNR2 P34972 1/20 0.37
ATM Q13315 1/20 0.37
HTR2A P28223 1/20 0.37
HTR2C P28335 1/20 0.37
NPC1 O15118 2/20 0.36
RAB9A P51151 2/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
MAPT P10636 1/20 0.36
APOBEC3A P31941 1/20 0.36
APOBEC3G Q9HC16 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL792496 0.96 GAA (0.41) ALDH1A1GAAALOX15TP53POLB
SCHEMBL792524 0.86 FABP4 (0.45) ALDH1A1GAAALOX15POLBTHRB
SCHEMBL792516 0.84 HTR7 (0.34) ALDH1A1GAATP53POLBTHRB
SCHEMBL14572851 0.83 HTR2A (0.37) ALDH1A1TP53L3MBTL1HTR2AHTR2C
SCHEMBL792539 0.79 DRD3 (0.41) ALDH1A1SIGMAR1HTR2AHTR2CSMN1; SMN2
SCHEMBL792525 0.76 GFER (0.41) ALDH1A1POLBHTR2AHTR2CNPC1
SCHEMBL792128 0.74 SIGMAR1 (0.32) ALDH1A1TP53POLBL3MBTL1SIGMAR1
SCHEMBL792066 0.70 MTNR1A (0.47) MAPK1NPC1RAB9AMAPT
SCHEMBL792588 0.69 ALDH1A1 (0.42) ALDH1A1SIGMAR1HTR2AHTR2CSMN1; SMN2
SCHEMBL30749787 0.67 HTR2A (0.66) GAAALOX15SIGMAR1MAPK1HTR2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120070409-A1 TETRACYCLIC FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR JAPAN TOBACCO INC. (JP) 2012-03-22 US disclosed
US-7977331-B1 Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor JAPAN TOBACCO INC. (JP) 2011-07-12 US disclosed
US-20070049593-A1 Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor JAPAN TOBACCO INC. (JP) 2007-03-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070049593-A1 Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor POLI, TERT, ZC3HAV1 ALDH1A1 750/4885GAA 374/4885ALOX15 3471/4885
US-20120070409-A1 TETRACYCLIC FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR POLI, TERT, ZC3HAV1 ALDH1A1 750/4885GAA 374/4885ALOX15 3471/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.